Q4 2024 Myriad Genetics Inc Earnings Call Transcript
Key Points
- Myriad Genetics Inc (MYGN) achieved 11% revenue growth in 2024 compared to 2023, driven by volume and revenue per test improvements.
- The company maintained industry-leading margins, achieved profitability, and reported positive adjusted EPS of $0.14.
- Myriad Genetics Inc (MYGN) announced an exclusive partnership with PATHOMIQ to enhance its oncology products with advanced AI technology.
- The company reported strong demand for its GeneSight test, with revenues up 14% in the fourth quarter.
- Myriad Genetics Inc (MYGN) has a strong liquidity position with $158 million in total liquidity from cash and cash equivalents and availability under its revolver.
- The company experienced slower-than-expected volume growth in Q4, particularly in its unaffected hereditary cancer business.
- There was a recent decision by UnitedHealthcare not to cover the GeneSight test, posing a reimbursement challenge.
- The integration of EMR workflows is taking longer than expected, affecting volume growth.
- Myriad Genetics Inc (MYGN) faces a challenging Q1 2025 due to a difficult growth comparison from favorable changes in estimates in Q1 2024.
- The company had to reverse a previously recorded $21 million contingent payment to Ravgen, impacting its future liquidity needs.
Good day, and thank you for standing by. Welcome to the Myriad Genetics fourth quarter 2024 financial earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to our speaker today, Matt Scalo. Please go ahead.
Thanks, Latania, and good afternoon, and welcome to the Myriad Genetics fourth quarter and full year 2024 earnings call. During the call, we will review the financial results we released today, and afterwards, we will host a question-and-answer session. Our quarterly earnings release was issued this afternoon on Form 8-K and can be found on our website at investor.myriad.com. I'm Matt Scalo, Senior Vice President of Investor Relations. And on the call with me today are Paul Diaz, our President and Chief Executive Officer; Scott Leffler, our Chief Financial Officer; Sam Raha, our Chief Operating Officer; and Mark Verratti, our Chief Commercial Officer.
This call can be heard live via webcast at
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
